-
Mashup Score: 0Apixaban outmatches rivaroxaban for VTE in study - 2 year(s) ago
These real-world findings may guide selection of initial anticoagulant therapy, according to authors of the paper.
Source: www.mdedge.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 3Anti-Xa Levels in Morbidly Obese Patients Using Apixaban or Rivaroxaban, Before and After Bariatric Surgery - PubMed - 2 year(s) ago
Plasma anti-Xa levels of apixaban in MO patients remained within the therapeutic range up to a body weight of 144 kg. In patients using rivaroxaban, no statistically significant relation between anti-Xa levels and bodyweight was found. After RYGB, plasma anti-Xa levels of apixaban were unaffected, w …
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet-
#Anti_Xa Levels in Morbidly #Obese Using #Apixaban or #Rivaroxaban, Before and After #Bariatric_Surgery https://t.co/Ijhohn1A7g
-
-
Mashup Score: 6
Background: Apixaban and rivaroxaban are replacing vitamin K antagonists for the treatment of venous thromboembolism (VTE) in adults; however, head-to-head comparisons remain limited. Objective: To assess the effectiveness and safety of apixaban compared with rivaroxaban in patients with VTE. Design: Retrospective new-user cohort study. Setting: U.S.-based commercial health care insurance…
Source: Annals of Internal MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
#ICYMI: patients with #VTE who initiated treatment using #apixaban had a lower rate of recurrent VTE and intracranial and GI bleeding events than those who first initiated treatment with #rivaroxaban: https://t.co/hXgWV56Bcf
-
-
Mashup Score: 0Apixaban outmatches rivaroxaban for VTE in study - 2 year(s) ago
These real-world findings may guide selection of initial anticoagulant therapy, according to authors of the paper.
Source: www.mdedge.comCategories: Latest Headlines, NeurologyTweet-
#Apixaban appears to be safer and more effective compared to rivaroxaban for reducing risk of #VTE and bleeding. https://t.co/03h7ZOj8yG https://t.co/0KrUWX8cuu
-
-
Mashup Score: 1
Background: Apixaban and rivaroxaban are replacing vitamin K antagonists for the treatment of venous thromboembolism (VTE) in adults; however, head-to-head comparisons remain limited. Objective: To assess the effectiveness and safety of apixaban compared with rivaroxaban in patients with VTE. Design: Retrospective new-user cohort study. Setting: U.S.-based commercial health care insurance…
Source: Annals of Internal MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
New from @DawwasGhadeer @UPennDBEI : patients with #VTE who initiated treatment using #apixaban had a lower rate of recurrent VTE and intracranial and GI bleeding events than those who first initiated treatment with #rivaroxaban: https://t.co/xBQbyCgVgC https://t.co/HvDim7kC2w
-
-
Mashup Score: 4Use of Anticoagulants and Dosing Appropriateness of Apixaban for New-Onset Atrial Fibrillation Among Hemodialysis Patients - 3 year(s) ago
Atrial fibrillation (AF) affects 21% of patients with end-stage kidney disease (ESKD) undergoing hemodialysis.1 AF is associated with two-fold higher adjusted risk of ischemic stroke and nine times higher adjusted mortality risk during the first 30 days after AF diagnosis in the hemodialysis population.2 In 2012 the U.S. Food and Drug Administration (FDA) approved apixaban for AF in patients with…
Categories: Latest Headlines, NephrologyTweet-
Use of Anticoagulants and Dosing Appropriateness of Apixaban for New-Onset Atrial Fibrillation Among Hemodialysis Patients https://t.co/G9OPVAke2r (FREE) @MinZhuo4 @Rishidesai11 @BWHKidney #hemodialysis #Apixaban https://t.co/0bamF9SgJy
-
-
Mashup Score: 0
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the filing of an Investigational Device Exemption (IDE) application to gain FDA approval to conduct the clinical study, “Safe and Timely Antithrombotic Removal – Direct Oral…
Source: finance.yahoo.comCategories: Cardiologists, Latest HeadlinesTweet-
CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on #Apixaban and #Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery #CTSO https://t.co/Zkl3HJUBIJ via @Yahoo
-
-
Mashup Score: 4
/PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using…
Source: www.prnewswire.comCategories: Cardiologists, Latest HeadlinesTweet-
DrugSorb-ATR Granted FDA Breakthrough Designation For Removal of #Apixaban & #Rivaroxaban In Urgent Cardiothoracic Surgery Honored to be leading their studies of this indication and removal of #Ticagrelor as well. COI: Research grant support https://t.co/ExZ34yOADi
-
-
Mashup Score: 0
AbstractAims. Using Scandinavian population-based registries, we assessed risk of stroke/systemic embolism (SE) and bleeding with non-vitamin K antagonist oral
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
In this Scandinavian study of >200k #AFib patients initiating oral #anticoagulation, #dabigatran, #apixaban & #rivaroxaban had similar rates of #stroke/SE as patients initiating #warfarin. #wondrmedical #EHJQCCO https://t.co/zwxdapTnik
-
-
Mashup Score: 0Apixaban linked to fewer adverse events in older adults with frailty, atrial fibrillation - 3 year(s) ago
Among older adults with atrial fibrillation, apixaban was linked to lower rates of adverse events across all frailty levels compared with warfarin, a retrospective observational study showed. In contrast, dabigatran and rivaroxaban were tied to lower adverse event rates in patients with atrial fibrillation (AF) who were not frail, according to researchers.
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
Among older adults with #atrialfibrillation, #apixaban was linked to lower rates of adverse events across all frailty levels compared with #warfarin, a retrospective observational study showed https://t.co/bsYOm31cXM
-
#Apixaban appears to be safer and more effective compared to rivaroxaban for reducing risk of VTE and bleeding. https://t.co/he0HZSy6H4 https://t.co/SJ2LAnN5Ck